<DOC>
	<DOCNO>NCT00292760</DOCNO>
	<brief_summary>This phase II open label study patient p53-deleted CLL require treatment . Both untreated previously treat patient eligible study entry . The trial consist give continuous alemtuzumab cyclical high-dose methyl-prednisone.Alentuzumab give intravenously first 4 week treatment ensure adequate serum level achieve quickly . The drug administer daily first week , commence dose 3mg , increase 10mg target dose 30mg tolerated.Thereafter alemtuzumab give dose 30mg thrice weekly . From week 5 , alemtuzumab give dose subcutaneous route administration . Methlyprednisolone give 5 consecutive day daily dose 1.0g/m2 , start Day 1 repeat cycle every 28 day . Treatment give 16 week ( i.e 4 cycle methylprednisolone ) . Treatment discontinue response 8 week , toxicity become unacceptable .</brief_summary>
	<brief_title>A Single-arm Phase II Study Alemtuzumab Combination With High-dose Methylprednisolone CLL Patients With p53 Deletion</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>At least 18 year old Written inform consent Confirmed diagnosis CLL SLL ( small mature lymphocytes n blood , bone marrow lymph nose express CD19 , CD5 , CD23 , weakk CD79b , weak clonally restrict immunoglobin light chain ) p53 deletion FISH least 20 % leukamia cell Treatment indicate ( Binet stage B C , stage A lyphocyte double time le 6 month , diseaserelated symptoms complication irrespective clinical stage ) WHO performance status 0 , 1 2 Both untreated previously treat patient eligible study Patients must none following : Active infection Known HIV infection Past history anaphylaxis follow exposure rat mouse CDRgrafted humanise monoclonal antibody Less 3 week since prior chemotherapy Use prior investigational agent within 6 week Pregnancy lactation Uncontrolled diabetes mellitus Uncontrolled hypertension Active peptic ulcer disease Other severe concurrent disease mental disorder Serum urea creatinine twice upper limit normal ( unless due uretic obstruction renal infiltration CLL/SLL ) Serum bilirubin twice upper limit normal ( unless due haemlysis liver infiltration CLL/SLL ) Persisting severe cytopenia due previous therapy rather disease ( neutrophils &lt; 0.5 x 109/l platelet &lt; 50 x 10/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>